poisar

Stock

Dr. Reddy's Laboratories Limited RDY

$11.76+0.26%

Overview

RDY market data

Price History

RDY price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
29.40
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
$50.35
Diluted earnings per share over the trailing twelve months.
Beta
0.25
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
70.4%
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$1,101.00 – $1,414.90
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $947.4K · P/B 2.76 · P/S 2.85.

Company News

8 captured
Dr. Reddy’s Laboratories Announces U.S. FDA Completes Inspection at Srikakulam Unit, Issues Form 483Benzinga · Jul 29, 2026, 4:29 PM
Why Dr. Reddy's Sank: Profit Plunge, Semaglutide Setback And Trump's Tariff ThreatBenzinga · Jul 22, 2026, 6:12 PM
Dr. Reddy's Laboratories shares are trading lower after the company reported worse-than-expected Q1 financial results. Also, President Trump announced a 100% import tariffs on imported generic drugs after a two-year grace period.Benzinga · Jul 22, 2026, 2:33 PM
Dr. Reddy's Executive During Earnings Conference Call Says Company Has Launched Generic Semaglutide Tablets In India; Not Practical To Move To U.S. Immediately Amid Tariff Environment; Working To Resume Semaglutide Supplies At Earliest; Hoping To Get Semaglutide To Market By NovemberBenzinga · Jul 22, 2026, 12:33 PM
Dr Reddy's Laboratories Q1 EPS $0.06 Misses $0.17 Estimate, Sales $853.000M Miss $925.530M EstimateBenzinga · Jul 22, 2026, 11:30 AM
Earnings Scheduled For July 22, 2026Benzinga · Jul 22, 2026, 11:11 AM
Antiparasitic Drugs Market Report Released — Examines Antimalarials, Anthelmintics, Antiprotozoals, Ectoparasiticides, and Neglected Tropical Disease TherapiesGlobenewswire Inc · Jul 20, 2026, 4:15 PM
Innoviva Specialty Therapeutics Inks Agreement With Dr. Reddy's Laboratories To Develop, Commercialize XACDURO To Treat Bacterial PneumoniaBenzinga · Jun 16, 2026, 12:10 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock